2023
PO83 Utilization of a Virtual Clinical Trial to Characterize Sensitivity of the Linear-Quadratic Model
Tien C, Draeger E, Guan F, Carlson D, Chen Z. PO83 Utilization of a Virtual Clinical Trial to Characterize Sensitivity of the Linear-Quadratic Model. Brachytherapy 2023, 22: s110. DOI: 10.1016/j.brachy.2023.06.184.Peer-Reviewed Original ResearchTumor control probabilityClinical trialsLinear-quadratic modelNumber of patientsPatient cohort sizeTCP curvesRadiobiological parametersVirtual clinical trialsGy-1Cohort sizeRange of dosesPatient outcomesReference cohortPatientsHeterogeneous cohortVirtual patientsNew trialsRadiobiological parameter valuesClonogenic populationPatient ordersControl probabilityGyInput model parametersTrialsCohortDose prescription and reporting in stereotactic body radiotherapy: A multi-institutional study
Das I, Yadav P, Andersen A, Chen Z, Huang L, Langer M, Lee C, Li L, Popple R, Rice R, Schiff P, Zhu T, Abazeed M. Dose prescription and reporting in stereotactic body radiotherapy: A multi-institutional study. Radiotherapy And Oncology 2023, 182: 109571. PMID: 36822361, PMCID: PMC10121952, DOI: 10.1016/j.radonc.2023.109571.Peer-Reviewed Original ResearchConceptsDose prescriptionTreatment-related toxicityClinical outcome comparisonStereotactic body radiotherapyMulti-institutional studyTreatment guidelinesTreatment disparitiesBody radiotherapyPTV volumeClinical trialsTreatment protocolOutcome comparisonsTreatment efficacyAbstractTextHypofractionated treatmentDosimetric parametersDose parametersDosimetric variabilityDosimetric variationsStandardized reportingLack of standardization
2017
HDR Monotherapy in Prostate Cancer: Radiobiological Considerations When Determining Biologically Effective Dose in Clinical Trials
Tien C, Carlson D, Nath R, Chen Z. HDR Monotherapy in Prostate Cancer: Radiobiological Considerations When Determining Biologically Effective Dose in Clinical Trials. Brachytherapy 2017, 16: s31. DOI: 10.1016/j.brachy.2017.04.038.Peer-Reviewed Original Research
2016
State of dose prescription and compliance to international standard (ICRU-83) in intensity modulated radiation therapy among academic institutions
Das IJ, Andersen A, Chen Z, Dimofte A, Glatstein E, Hoisak J, Huang L, Langer MP, Lee C, Pacella M, Popple RA, Rice R, Smilowitz J, Sponseller P, Zhu T. State of dose prescription and compliance to international standard (ICRU-83) in intensity modulated radiation therapy among academic institutions. Practical Radiation Oncology 2016, 7: e145-e155. PMID: 28274405, DOI: 10.1016/j.prro.2016.11.003.Peer-Reviewed Original ResearchConceptsDose-volume histogramsDose prescriptionRadiation therapyHomogeneity indexICRU-83Stereotactic body radiation therapyBody radiation therapyTreatment sitesInstitutional review board clearanceLung sitesClinical trialsPelvic sitesPrescribed doseInternational guidelinesTumor siteArc therapyPatient treatmentTarget volumeTherapyPatientsDoseLevels of dosePrescriptionP-valueDose delivery
2009
AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137
Nath R, Bice WS, Butler WM, Chen Z, Meigooni AS, Narayana V, Rivard MJ, Yu Y. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137. Medical Physics 2009, 36: 5310-5322. PMID: 19994539, PMCID: PMC2776817, DOI: 10.1118/1.3246613.Peer-Reviewed Original ResearchConceptsBiological equivalent doseTumor volumeDose prescriptionStandard of careProstate cancer patientsPermanent interstitial brachytherapyAcute single dosesEffects of edemaCancer patientsSurgical traumaIntraoperative implantationSingle dosesClinical trialsProstate cancerRadiobiological modelsCurrent recommendationsInterstitial brachytherapyMore specific guidelinesRoutine patient treatmentsDifferent dose distributionsTreatment planPatient treatmentTarget volumeMost implantsDose distribution